1. Home
  2. BCG vs RNTX Comparison

BCG vs RNTX Comparison

Compare BCG & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCG
  • RNTX
  • Stock Information
  • Founded
  • BCG 2016
  • RNTX 2001
  • Country
  • BCG United States
  • RNTX United States
  • Employees
  • BCG N/A
  • RNTX N/A
  • Industry
  • BCG
  • RNTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • BCG
  • RNTX Health Care
  • Exchange
  • BCG Nasdaq
  • RNTX Nasdaq
  • Market Cap
  • BCG 32.5M
  • RNTX 28.0M
  • IPO Year
  • BCG N/A
  • RNTX N/A
  • Fundamental
  • Price
  • BCG $1.71
  • RNTX $1.18
  • Analyst Decision
  • BCG
  • RNTX Hold
  • Analyst Count
  • BCG 0
  • RNTX 1
  • Target Price
  • BCG N/A
  • RNTX N/A
  • AVG Volume (30 Days)
  • BCG 18.7K
  • RNTX 127.1K
  • Earning Date
  • BCG 11-13-2025
  • RNTX 11-13-2025
  • Dividend Yield
  • BCG N/A
  • RNTX N/A
  • EPS Growth
  • BCG N/A
  • RNTX N/A
  • EPS
  • BCG N/A
  • RNTX N/A
  • Revenue
  • BCG $173,961,000.00
  • RNTX N/A
  • Revenue This Year
  • BCG N/A
  • RNTX N/A
  • Revenue Next Year
  • BCG N/A
  • RNTX N/A
  • P/E Ratio
  • BCG N/A
  • RNTX N/A
  • Revenue Growth
  • BCG 7.45
  • RNTX N/A
  • 52 Week Low
  • BCG $1.68
  • RNTX $1.04
  • 52 Week High
  • BCG $6.55
  • RNTX $4.40
  • Technical
  • Relative Strength Index (RSI)
  • BCG 34.59
  • RNTX 46.50
  • Support Level
  • BCG $1.75
  • RNTX $1.07
  • Resistance Level
  • BCG $2.10
  • RNTX $1.43
  • Average True Range (ATR)
  • BCG 0.10
  • RNTX 0.13
  • MACD
  • BCG -0.01
  • RNTX -0.00
  • Stochastic Oscillator
  • BCG 5.95
  • RNTX 28.44

About BCG Binah Capital Group Inc. Common Stock

Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.

About RNTX Rein Therapeutics Inc. Common Stock

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: